Opinion|Videos|June 26, 2024
Dr Rugo and Dr O’Shaughnessy Discuss the monarchE Trial
Results from the monarchE trial are analyzed by Hope Rugo, MD, and Joyce O'Shaughnessy, MD.
Advertisement
Video content above is prompted by the following:
- Abemaciclib is recommended by NCCN in this setting based on the monarchE trial, which recently released its 5-year long-term data in January.
- Describe the updated survival data, including both invasive disease-free survival and overall survival. How have these survival rates evolved with each annual analysis?
- Please highlight the follow-up time of patients.
- Are there specific subgroups of patients within the monarchE trial who derived particular benefit from the addition of abemaciclib?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5